Please assess the completion status of the following clinical trial:

Trial Title: A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have stage IIIB (malignant pleural or pericardial effusion) or stage IV disease.~* Be chemotherapy naïve.~* Have measurable disease by RECIST, defined as at least 1 lesion that can be accurately measured in at least 1 dimension as \>20 mm with conventional techniques or \>10 mm with spiral CT scan; the longest diameter is to be recorded.~* Are 18 years of age or older.~* Have a life expectancy greater than 3 months.~* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~* Are able to provide written informed consent in accordance with all applicable regulations and follow the study procedures. Patients must be capable of understanding the investigational nature, potential risks and benefits of the study.~* The ability to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of Alimta and the ability to take folic acid, Vitamin B12 and dexamethasone according to protocol.~Exclusion Criteria:~* Have had prior chemotherapy (or an epidermal growth factor receptor (EGFR TKI) for treatment of advanced disease~* Intrathoracic lung carcinoma of squamous cell histology~* History of hemoptysis (bright red blood of 1/2 teaspoon or more per episode) within 1 month prior to study enrollment.~* Current, ongoing treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin).~* Current or recent (within 10 days of enrollment) use of aspirin (\>325 mg/day) or chronic use of other NSAIDs.~* Cardiovascular concerns.~* Have had radiation therapy within 2 weeks prior to enrollment.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study.~* Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 0.~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1.~* Serious, non-healing wound, ulcer, or bone fracture.~* Have inadequate organ function at the Screening visit.~* Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).~* Have uncontrolled active systemic infection requiring treatment.~* Have had treatment for a cancer other than NSCLC within 5 years prior to enrollment, with the exception of basal cell carcinoma or cervical cancer in situ.~* Have known human immunodeficiency virus (HIV) positive or hepatitis B surface antigen-positive status or known active hepatitis C infection. Patients assessed by the investigator to be at risk for HIV, hepatitis B or C infection should be tested in accordance with local regulations.~* Are a pregnant or breast-feeding female. Confirmation that the patient is not pregnant must be established by a negative serum Beta-human chorionic gonadotropin (β-hCG) pregnancy test result obtained during the Screening Period. Pregnancy testing is not required for post-menopausal or surgically sterilized women.~* Are unwilling to employ adequate means of contraception (condoms, diaphragm, birth control pills, injections, intrauterine device, or abstinence).~* Are currently receiving or have previously received an investigational agent for any reason within 4 weeks of enrollment.~* Presence of third space fluid which cannot be controlled by drainage.~* Inability to comply with study and/or follow-up procedures.~* Prior history of hypertensive crisis or hypertensive encephalopathy.~* History of stroke or transient ischemic attack within 6 months prior to Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed, Cisplatin, Bevacizumab (Type: EXPERIMENTAL): Chemotherapy infusion on Day 1 of a 3-week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues